Share Price and Basic Stock Data
Last Updated: October 10, 2025, 8:56 pm
| PEG Ratio | -31.58 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Tata Chemicals Ltd operates in the inorganic chemicals sector, particularly focusing on caustic soda and soda ash. As of October 2023, the company is trading at ₹922 with a market capitalization of ₹23,465 Cr. Over the past year, Tata Chemicals has shown fluctuations in revenue, with sales peaking at ₹4,407 Cr in March 2023, before declining to ₹3,998 Cr by September 2023. The decline in revenue is concerning when compared to the prior year’s performance, where total sales for FY 2022-23 were ₹16,789 Cr, up from ₹12,622 Cr in FY 2021-22. This indicates a year-on-year growth of 33.7%, but the recent quarterly trends suggest a potential slowdown in momentum. The company’s operational efficiency, as indicated by the operating profit margin (OPM), has also seen variability, peaking at 25% in June 2022 but dropping to 15% by December 2023.
Profitability and Efficiency Metrics
Profitability metrics for Tata Chemicals have displayed significant volatility. The net profit for the latest fiscal year (FY 2022-23) stood at ₹2,434 Cr, translating to an EPS of ₹90.93. However, projections for FY 2024 indicate a sharp decline in profitability, with net profit expected to drop to ₹435 Cr, resulting in an EPS of just ₹10.52. The return on equity (ROE) is currently at a low 1.20%, significantly below the industry average of approximately 12-15%, indicating inefficiency in generating returns for shareholders. The return on capital employed (ROCE) is similarly low at 3.96%, suggesting challenges in utilizing capital effectively. Moreover, the cash conversion cycle (CCC) stands at 53 days, which is relatively efficient but still indicates room for improvement in managing inventory and receivables.
Balance Sheet Strength and Financial Ratios
Tata Chemicals’ balance sheet reflects a cautious financial strategy, with total borrowings of ₹7,072 Cr against reserves of ₹21,339 Cr, yielding a debt-to-equity ratio of 0.22, which is considered healthy. The interest coverage ratio (ICR) is robust at 5.91x, suggesting that the company can comfortably meet its interest obligations. However, the company’s book value per share has increased to ₹906.43, indicating a solid asset base. Despite this, the price-to-book value (P/BV) ratio stands at 1.24x, suggesting that the stock may be overvalued relative to its book value. Furthermore, the company’s dividend payout ratio is exceptionally high at 166.41% for the last fiscal year, which raises concerns about sustainability, given the projected decline in earnings.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Tata Chemicals reveals a stable yet cautious investor sentiment. Promoters hold 37.98% of the company, while foreign institutional investors (FIIs) have decreased their stake to 12.85%, down from 14.92% in September 2022. Domestic institutional investors (DIIs) have maintained a steady presence at 22.61%, indicating confidence from local institutions. The public shareholding is at 26.53%, reflecting a broad base of retail investors. The increase in the number of shareholders to 6,77,130 by June 2025 suggests growing interest in the company. However, the declining FII interest may be a red flag, indicating potential concerns about the company’s future performance and market perception.
Outlook, Risks, and Final Insight
Looking ahead, Tata Chemicals faces both opportunities and challenges. The anticipated decline in net profit and EPS raises concerns about its ability to sustain growth, especially with profitability metrics trending downward. Key risks include fluctuating commodity prices and increased competition in the chemical sector, which could further pressure margins. However, the company’s strong balance sheet and low debt levels provide a buffer against economic uncertainties. Overall, while Tata Chemicals has a solid foundation with significant reserves and a stable operational base, the declining profitability and reduced FII interest present challenges that need addressing. Investors should remain cautious, focusing on upcoming quarterly results to gauge whether the company can reverse its current trajectory and regain market confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Tata Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 20.9 Cr. | 45.5 | 65.0/37.5 | 10.5 | 0.00 % | 0.48 % | 13.7 % | 10.0 | |
| Standard Industries Ltd | 121 Cr. | 18.7 | 31.1/17.5 | 18.6 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,163 Cr. | 567 | 900/484 | 772 | 2.79 % | 0.34 % | 1.13 % | 10.0 | |
| GHCL Ltd | 6,071 Cr. | 632 | 779/511 | 9.83 | 364 | 1.90 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 23,025 Cr. | 903 | 1,247/756 | 54.6 | 847 | 1.22 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,850.60 Cr | 462.20 | 39.34 | 382.68 | 1.02% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,995 | 4,239 | 4,148 | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 |
| Expenses | 2,980 | 3,319 | 3,317 | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 |
| Operating Profit | 1,015 | 920 | 831 | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 |
| OPM % | 25% | 22% | 20% | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% |
| Other Income | 71 | 102 | 30 | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 |
| Interest | 80 | 86 | 107 | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 |
| Depreciation | 213 | 218 | 227 | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 |
| Profit before tax | 793 | 718 | 527 | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 |
| Tax % | 20% | 5% | 19% | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% |
| Net Profit | 637 | 680 | 425 | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 |
| EPS in Rs | 23.12 | 24.65 | 15.35 | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 |
Last Updated: August 1, 2025, 9:30 pm
Below is a detailed analysis of the quarterly data for Tata Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,719.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,509.00 Cr. (Mar 2025) to 3,719.00 Cr., marking an increase of 210.00 Cr..
- For Expenses, as of Jun 2025, the value is 3,070.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,182.00 Cr. (Mar 2025) to 3,070.00 Cr., marking a decrease of 112.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 649.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Mar 2025) to 649.00 Cr., marking an increase of 322.00 Cr..
- For OPM %, as of Jun 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 17.00%, marking an increase of 8.00%.
- For Other Income, as of Jun 2025, the value is 138.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 109.00 Cr..
- For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 10.00 Cr..
- For Depreciation, as of Jun 2025, the value is 280.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 293.00 Cr. (Mar 2025) to 280.00 Cr., marking a decrease of 13.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 360.00 Cr.. The value appears strong and on an upward trend. It has increased from -74.00 Cr. (Mar 2025) to 360.00 Cr., marking an increase of 434.00 Cr..
- For Tax %, as of Jun 2025, the value is 12.00%. The value appears to be increasing, which may not be favorable. It has increased from -34.00% (Mar 2025) to 12.00%, marking an increase of 46.00%.
- For Net Profit, as of Jun 2025, the value is 316.00 Cr.. The value appears strong and on an upward trend. It has increased from -49.00 Cr. (Mar 2025) to 316.00 Cr., marking an increase of 365.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.89. The value appears strong and on an upward trend. It has increased from -2.20 (Mar 2025) to 9.89, marking an increase of 12.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 5:34 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,885 | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 |
| Expenses | 15,200 | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 |
| Operating Profit | 686 | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 |
| OPM % | 4% | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% |
| Other Income | -154 | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 |
| Interest | 579 | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 |
| Depreciation | 471 | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 |
| Profit before tax | -519 | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 |
| Tax % | 56% | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% |
| Net Profit | -811 | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 |
| EPS in Rs | -40.50 | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 |
| Dividend Payout % | -25% | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 198.89% | 25.44% | 22.66% | 118.96% | -48.67% | 421.12% | -93.97% | 222.25% | 73.24% | -82.13% | -11.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | -173.45% | -2.77% | 96.30% | -167.63% | 469.79% | -515.09% | 316.22% | -149.01% | -155.37% | 71.09% |
Tata Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -48% |
| 3 Years: | -40% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 25% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 4:00 am
Balance Sheet
Last Updated: June 16, 2025, 12:09 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,311 | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 |
| Borrowings | 8,393 | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 |
| Other Liabilities | 6,127 | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 |
| Total Liabilities | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 |
| Fixed Assets | 11,007 | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 |
| CWIP | 468 | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 |
| Investments | 441 | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 |
| Other Assets | 8,171 | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 |
| Total Assets | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 |
Below is a detailed analysis of the balance sheet data for Tata Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 255.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 255.00 Cr..
- For Reserves, as of Mar 2025, the value is 21,339.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21,986.00 Cr. (Mar 2024) to 21,339.00 Cr., marking a decrease of 647.00 Cr..
- For Borrowings, as of Mar 2025, the value is 7,072.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,563.00 Cr. (Mar 2024) to 7,072.00 Cr., marking an increase of 1,509.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 9,084.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,907.00 Cr. (Mar 2024) to 9,084.00 Cr., marking an increase of 177.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 37,750.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36,711.00 Cr. (Mar 2024) to 37,750.00 Cr., marking an increase of 1,039.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 19,600.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,861.00 Cr. (Mar 2024) to 19,600.00 Cr., marking an increase of 1,739.00 Cr..
- For CWIP, as of Mar 2025, the value is 1,913.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,217.00 Cr. (Mar 2024) to 1,913.00 Cr., marking a decrease of 304.00 Cr..
- For Investments, as of Mar 2025, the value is 9,144.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9,739.00 Cr. (Mar 2024) to 9,144.00 Cr., marking a decrease of 595.00 Cr..
- For Other Assets, as of Mar 2025, the value is 7,093.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,894.00 Cr. (Mar 2024) to 7,093.00 Cr., marking an increase of 199.00 Cr..
- For Total Assets, as of Mar 2025, the value is 37,750.00 Cr.. The value appears strong and on an upward trend. It has increased from 36,711.00 Cr. (Mar 2024) to 37,750.00 Cr., marking an increase of 1,039.00 Cr..
Notably, the Reserves (21,339.00 Cr.) exceed the Borrowings (7,072.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 678.00 | -7.00 | -7.00 | -5.00 | -3.00 | -5.00 | -6.00 | -5.00 | -5.00 | -3.00 | -3.00 | -6.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 |
| Inventory Days | 96 | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 |
| Days Payable | 119 | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 |
| Cash Conversion Cycle | 52 | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 |
| Working Capital Days | 11 | -4 | 31 | -4 | 27 | -2 | -102 | 27 | -29 | 29 | -22 | -21 |
| ROCE % | 3% | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 4,260,000 | 0.74 | 437.95 | 4,260,000 | 2025-04-22 13:31:13 | 0% |
| Kotak Flexicap Fund - Regular Plan | 3,750,000 | 0.87 | 385.52 | 3,750,000 | 2025-04-22 03:17:28 | 0% |
| Kotak Equity Opportunities Fund - Regular Plan | 2,064,884 | 1.16 | 212.28 | 2,064,884 | 2025-04-22 17:25:36 | 0% |
| Nippon India Growth Fund | 1,561,427 | 0.66 | 160.52 | 1,561,427 | 2025-04-22 17:25:36 | 0% |
| DSP Mid Cap Fund | 1,382,053 | 0.86 | 142.08 | 1,382,053 | 2025-04-22 03:17:28 | 0% |
| DSP Equity Opportunities Fund | 717,459 | 0.69 | 73.76 | 717,459 | 2025-04-22 17:25:36 | 0% |
| HDFC Large and Mid Cap Fund - Regular Plan | 508,000 | 0.33 | 52.22 | 508,000 | 2025-04-22 03:17:28 | 0% |
| Quant Active Fund | 217,000 | 0.27 | 22.31 | 217,000 | 2025-04-22 03:17:28 | 0% |
| Edelweiss Arbitrage Fund | 149,600 | 0.19 | 15.38 | 149,600 | 2025-04-22 03:17:28 | 0% |
| Kotak Multicap Fund | 143,500 | 0.17 | 14.75 | 143,500 | 2025-04-22 03:17:28 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.52 | 90.95 | 49.37 | 10.06 | 275.02 |
| Diluted EPS (Rs.) | 10.52 | 90.95 | 49.37 | 10.06 | 275.02 |
| Cash EPS (Rs.) | 52.82 | 130.43 | 77.91 | 45.91 | 309.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 906.43 | 809.49 | 751.80 | 594.25 | 536.12 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 906.43 | 809.49 | 751.80 | 594.25 | 536.12 |
| Revenue From Operations / Share (Rs.) | 604.75 | 658.39 | 495.33 | 400.27 | 406.43 |
| PBDIT / Share (Rs.) | 122.86 | 158.43 | 100.49 | 68.09 | 88.70 |
| PBIT / Share (Rs.) | 84.43 | 123.45 | 68.85 | 38.29 | 62.55 |
| PBT / Share (Rs.) | 29.88 | 107.45 | 56.53 | 23.87 | 49.13 |
| Net Profit / Share (Rs.) | 14.39 | 95.45 | 46.27 | 16.11 | 283.81 |
| NP After MI And SOA / Share (Rs.) | 10.51 | 90.86 | 49.35 | 10.06 | 274.95 |
| PBDIT Margin (%) | 20.31 | 24.06 | 20.28 | 17.01 | 21.82 |
| PBIT Margin (%) | 13.96 | 18.75 | 13.90 | 9.56 | 15.38 |
| PBT Margin (%) | 4.94 | 16.32 | 11.41 | 5.96 | 12.08 |
| Net Profit Margin (%) | 2.37 | 14.49 | 9.34 | 4.02 | 69.82 |
| NP After MI And SOA Margin (%) | 1.73 | 13.80 | 9.96 | 2.51 | 67.64 |
| Return on Networth / Equity (%) | 1.20 | 11.74 | 6.88 | 1.79 | 54.32 |
| Return on Capital Employeed (%) | 7.01 | 10.43 | 6.55 | 4.08 | 7.71 |
| Return On Assets (%) | 0.72 | 6.60 | 3.71 | 0.90 | 25.30 |
| Long Term Debt / Equity (X) | 0.13 | 0.28 | 0.20 | 0.36 | 0.26 |
| Total Debt / Equity (X) | 0.22 | 0.30 | 0.37 | 0.38 | 0.41 |
| Asset Turnover Ratio (%) | 0.42 | 0.48 | 0.40 | 0.14 | 0.14 |
| Current Ratio (X) | 1.05 | 1.66 | 1.23 | 1.49 | 1.11 |
| Quick Ratio (X) | 0.63 | 1.15 | 0.90 | 1.11 | 0.84 |
| Inventory Turnover Ratio (X) | 1.07 | 1.22 | 1.22 | 0.50 | 0.44 |
| Dividend Payout Ratio (NP) (%) | 166.41 | 13.72 | 20.25 | 109.30 | 5.47 |
| Dividend Payout Ratio (CP) (%) | 35.73 | 9.90 | 12.34 | 27.59 | 5.00 |
| Earning Retention Ratio (%) | -66.41 | 86.28 | 79.75 | -9.30 | 94.53 |
| Cash Earning Retention Ratio (%) | 64.27 | 90.10 | 87.66 | 72.41 | 95.00 |
| Interest Coverage Ratio (X) | 5.91 | 9.95 | 8.46 | 4.72 | 6.61 |
| Interest Coverage Ratio (Post Tax) (X) | 3.34 | 7.04 | 4.91 | 2.12 | 4.02 |
| Enterprise Value (Cr.) | 32847.30 | 31130.10 | 31228.96 | 24062.00 | 9753.04 |
| EV / Net Operating Revenue (X) | 2.13 | 1.85 | 2.47 | 2.36 | 0.94 |
| EV / EBITDA (X) | 10.48 | 7.71 | 12.20 | 13.87 | 4.31 |
| MarketCap / Net Operating Revenue (X) | 1.79 | 1.48 | 1.97 | 1.88 | 0.54 |
| Retention Ratios (%) | -66.41 | 86.27 | 79.74 | -9.30 | 94.52 |
| Price / BV (X) | 1.24 | 1.26 | 1.36 | 1.34 | 0.44 |
| Price / Net Operating Revenue (X) | 1.79 | 1.48 | 1.97 | 1.88 | 0.54 |
| EarningsYield | 0.01 | 0.09 | 0.05 | 0.01 | 1.23 |
After reviewing the key financial ratios for Tata Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 10.52. This value is within the healthy range. It has decreased from 90.95 (Mar 23) to 10.52, marking a decrease of 80.43.
- For Diluted EPS (Rs.), as of Mar 24, the value is 10.52. This value is within the healthy range. It has decreased from 90.95 (Mar 23) to 10.52, marking a decrease of 80.43.
- For Cash EPS (Rs.), as of Mar 24, the value is 52.82. This value is within the healthy range. It has decreased from 130.43 (Mar 23) to 52.82, marking a decrease of 77.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 906.43. It has increased from 809.49 (Mar 23) to 906.43, marking an increase of 96.94.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 906.43. It has increased from 809.49 (Mar 23) to 906.43, marking an increase of 96.94.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 604.75. It has decreased from 658.39 (Mar 23) to 604.75, marking a decrease of 53.64.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 122.86. This value is within the healthy range. It has decreased from 158.43 (Mar 23) to 122.86, marking a decrease of 35.57.
- For PBIT / Share (Rs.), as of Mar 24, the value is 84.43. This value is within the healthy range. It has decreased from 123.45 (Mar 23) to 84.43, marking a decrease of 39.02.
- For PBT / Share (Rs.), as of Mar 24, the value is 29.88. This value is within the healthy range. It has decreased from 107.45 (Mar 23) to 29.88, marking a decrease of 77.57.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 14.39. This value is within the healthy range. It has decreased from 95.45 (Mar 23) to 14.39, marking a decrease of 81.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 10.51. This value is within the healthy range. It has decreased from 90.86 (Mar 23) to 10.51, marking a decrease of 80.35.
- For PBDIT Margin (%), as of Mar 24, the value is 20.31. This value is within the healthy range. It has decreased from 24.06 (Mar 23) to 20.31, marking a decrease of 3.75.
- For PBIT Margin (%), as of Mar 24, the value is 13.96. This value is within the healthy range. It has decreased from 18.75 (Mar 23) to 13.96, marking a decrease of 4.79.
- For PBT Margin (%), as of Mar 24, the value is 4.94. This value is below the healthy minimum of 10. It has decreased from 16.32 (Mar 23) to 4.94, marking a decrease of 11.38.
- For Net Profit Margin (%), as of Mar 24, the value is 2.37. This value is below the healthy minimum of 5. It has decreased from 14.49 (Mar 23) to 2.37, marking a decrease of 12.12.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 1.73. This value is below the healthy minimum of 8. It has decreased from 13.80 (Mar 23) to 1.73, marking a decrease of 12.07.
- For Return on Networth / Equity (%), as of Mar 24, the value is 1.20. This value is below the healthy minimum of 15. It has decreased from 11.74 (Mar 23) to 1.20, marking a decrease of 10.54.
- For Return on Capital Employeed (%), as of Mar 24, the value is 7.01. This value is below the healthy minimum of 10. It has decreased from 10.43 (Mar 23) to 7.01, marking a decrease of 3.42.
- For Return On Assets (%), as of Mar 24, the value is 0.72. This value is below the healthy minimum of 5. It has decreased from 6.60 (Mar 23) to 0.72, marking a decrease of 5.88.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.28 (Mar 23) to 0.13, marking a decrease of 0.15.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.22. This value is within the healthy range. It has decreased from 0.30 (Mar 23) to 0.22, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.42. It has decreased from 0.48 (Mar 23) to 0.42, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 24, the value is 1.05. This value is below the healthy minimum of 1.5. It has decreased from 1.66 (Mar 23) to 1.05, marking a decrease of 0.61.
- For Quick Ratio (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 23) to 0.63, marking a decrease of 0.52.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.07. This value is below the healthy minimum of 4. It has decreased from 1.22 (Mar 23) to 1.07, marking a decrease of 0.15.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 166.41. This value exceeds the healthy maximum of 50. It has increased from 13.72 (Mar 23) to 166.41, marking an increase of 152.69.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 35.73. This value is within the healthy range. It has increased from 9.90 (Mar 23) to 35.73, marking an increase of 25.83.
- For Earning Retention Ratio (%), as of Mar 24, the value is -66.41. This value is below the healthy minimum of 40. It has decreased from 86.28 (Mar 23) to -66.41, marking a decrease of 152.69.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 64.27. This value is within the healthy range. It has decreased from 90.10 (Mar 23) to 64.27, marking a decrease of 25.83.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 5.91. This value is within the healthy range. It has decreased from 9.95 (Mar 23) to 5.91, marking a decrease of 4.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 3.34. This value is within the healthy range. It has decreased from 7.04 (Mar 23) to 3.34, marking a decrease of 3.70.
- For Enterprise Value (Cr.), as of Mar 24, the value is 32,847.30. It has increased from 31,130.10 (Mar 23) to 32,847.30, marking an increase of 1,717.20.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has increased from 1.85 (Mar 23) to 2.13, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 24, the value is 10.48. This value is within the healthy range. It has increased from 7.71 (Mar 23) to 10.48, marking an increase of 2.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.79. This value is within the healthy range. It has increased from 1.48 (Mar 23) to 1.79, marking an increase of 0.31.
- For Retention Ratios (%), as of Mar 24, the value is -66.41. This value is below the healthy minimum of 30. It has decreased from 86.27 (Mar 23) to -66.41, marking a decrease of 152.68.
- For Price / BV (X), as of Mar 24, the value is 1.24. This value is within the healthy range. It has decreased from 1.26 (Mar 23) to 1.24, marking a decrease of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.79. This value is within the healthy range. It has increased from 1.48 (Mar 23) to 1.79, marking an increase of 0.31.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.01, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Tata Chemicals Ltd:
- Net Profit Margin: 2.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.01% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.2% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.63
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.6 (Industry average Stock P/E: 19.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.22
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Bombay House, 24, Homi Mody Street, Mumbai Maharashtra 400001 | investors@tatachemicals.com http://www.tatachemicals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Padmanabhan | Chairman |
| Mr. R Mukundan | Managing Director & CEO |
| Mr. Modan Saha | Director |
| Mrs. Padmini Khare Kaicker | Independent Director |
| Mr. Rajiv Dube | Independent Director |
| Dr. C V Natraj | Independent Director |
| Mr. K B S Anand | Independent Director |
FAQ
What is the intrinsic value of Tata Chemicals Ltd?
Tata Chemicals Ltd's intrinsic value (as of 11 October 2025) is 449.38 which is 50.23% lower the current market price of 903.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹23,025 Cr. market cap, FY2025-2026 high/low of 1,247/756, reserves of ₹21,339 Cr, and liabilities of 37,750 Cr.
What is the Market Cap of Tata Chemicals Ltd?
The Market Cap of Tata Chemicals Ltd is 23,025 Cr..
What is the current Stock Price of Tata Chemicals Ltd as on 11 October 2025?
The current stock price of Tata Chemicals Ltd as on 11 October 2025 is 903.
What is the High / Low of Tata Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Tata Chemicals Ltd stocks is 1,247/756.
What is the Stock P/E of Tata Chemicals Ltd?
The Stock P/E of Tata Chemicals Ltd is 54.6.
What is the Book Value of Tata Chemicals Ltd?
The Book Value of Tata Chemicals Ltd is 847.
What is the Dividend Yield of Tata Chemicals Ltd?
The Dividend Yield of Tata Chemicals Ltd is 1.22 %.
What is the ROCE of Tata Chemicals Ltd?
The ROCE of Tata Chemicals Ltd is 3.96 %.
What is the ROE of Tata Chemicals Ltd?
The ROE of Tata Chemicals Ltd is 1.20 %.
What is the Face Value of Tata Chemicals Ltd?
The Face Value of Tata Chemicals Ltd is 10.0.